The purpose of the present study was to evaluate the effects on lipid metabolism of a new low-dose monophasic combination oral contraceptive with 100 µg levonorgestrel and 20 µg ethinylestradiol. Sixty healthy women aged 18–45 years were administered the medication during three cycles. The study participants were screened for lipid changes. The differences in cholesterol and triglyceride levels were not statistically significant, but high-density lipoprotein levels were significantly lower and low-density lipoprotein levels were significantly higher than the baseline. Women at risk of cardiovascular disease should be carefully monitored even when using low-dose preparations.